Zobrazeno 1 - 10
of 583
pro vyhledávání: '"Kim Lyerly"'
Autor:
Brooke E. Wilson, Richard Sullivan, Richard Peto, Bello Abubakar, Christopher Booth, Gustavo Werutsky, Cary Adams, Agnes Saint-Raymond, Thomas R. Fleming, Kim Lyerly, Julie R. Gralow
Publikováno v:
JCO Global Oncology, Vol , Iss 9 (2023)
Rapidly expanding systemic treatment options, combined with improved screening, diagnostic, surgical, and radiotherapy techniques, have led to improved survival outcomes for many cancers over time. However, these overall survival gains have dispropor
Externí odkaz:
https://doaj.org/article/a444ea993fd74de8be9391dd44ba8022
Autor:
Jun Ren, Congcong Li, Dazhao Xu, Kun Wan, Chuxiong Zeng, Lina Hu, Xianzhi Guo, Feifei Huo, Xiumei Rong, Xinna Zhou, Tiecheng Wu, Xiaoli Wang, Bo Sun, JingJing Lou, Amy Hobeika, Michael A. Morse, Herbert Kim Lyerly
Publikováno v:
International Journal of Hyperthermia, Vol 41, Iss 1 (2024)
Purpose Immune checkpoint inhibitors (ICIs) and target therapy have provided the clinical efficacy for improving the clinical progression-free survival (PFS) and overall survival (OS) for patients with renal cell carcinoma (RCC). There has been littl
Externí odkaz:
https://doaj.org/article/bc311b8df66144a488149fa33a320674
Autor:
Robert D. Marek, Selena Halabi, Mu-En Wang, Jason McBane, Junping Wei, Tao Wang, Xiao Yang, Congxiao Liu, Gangjun Lei, Herbert Kim Lyerly, Ming Chen, Timothy N. Trotter, Zachary C. Hartman
Publikováno v:
Vaccines, Vol 12, Iss 11, p 1273 (2024)
Background/Objectives: Androgen receptor (AR) expression and signaling are critical for the progression of prostate cancer and have been the therapeutic focus of prostate cancer for over 50 years. While a variety of agents have been developed to targ
Externí odkaz:
https://doaj.org/article/c963995c0b8d4b7f83e39d65de5281db
Autor:
Bin Yu, Igor Akushevich, Arseniy P. Yashkin, Anatoliy I. Yashin, H. Kim Lyerly, Julia Kravchenko
Publikováno v:
BMC Public Health, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background There are prominent geographic disparities in the life expectancy (LE) of older US adults between the states with the highest (leading states) and lowest (lagging states) LE and their causes remain poorly understood. Heart failure
Externí odkaz:
https://doaj.org/article/4ccd0643987e45ce821dd5f8bd9c719c
Autor:
Jack Y. Lee, Bianca Nguyen, Anandaroop Mukhopadhyay, Mia Han, Jun Zhang, Ravindra Gujar, Jon Salazar, Reneta Hermiz, Lauren Svenson, Erica Browning, H. Kim Lyerly, David A. Canton, Daniel Fisher, Adil Daud, Alain Algazi, Joseph Skitzki, Christopher G. Twitty
Publikováno v:
Molecular Therapy: Oncolytics, Vol 25, Iss , Pp 174-188 (2022)
Clinical studies have demonstrated that local expression of the cytokine IL-12 drives interferon-gamma expression and recruits T cells to the tumor microenvironment, ultimately yielding durable systemic T cell responses. Interrogation of longitudinal
Externí odkaz:
https://doaj.org/article/e9b02e1da6b143caba62a394755fbbb0
Autor:
Xiao Yang, Michael A Morse, Takuya Osada, Amy Hobeika, Herbert Kim Lyerly, Zachary Conrad Hartman, Hiroshi Nagata, Kensuke Kaneko, Chaitanya R Acharya, Philip F Hughes, Timothy A J Haystead
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 9 (2022)
Background We previously demonstrated potent antitumor activity against human breast cancer xenografts using photodynamic therapy (PDT) targeting a novel tumor-specific photosensitizer (HS201), which binds heat shock protein 90 (HS201-PDT). However,
Externí odkaz:
https://doaj.org/article/565e94da5b9048f6b975c2f576e21cce
Autor:
Darya Kizub, Cathyryne K. Manner, Katy Graef, Bello Abubakar, Jackson Orem, Folakemi Odedina, Mojisola Christianah Adeyeye, Gertrude Nakigudde, Kassa Ayalew, Chitkala Kalidas, Herbert Kim Lyerly, Thea Norman, Lola Fashoyin-Aje, Jamie Freedman, Jennifer Dent, Bill Cance, Julie Gralow
Publikováno v:
JCO Global Oncology, Vol , Iss 8 (2022)
Patients of African ancestry are not well-represented in cancer clinical trials despite bearing a disproportionate share of mortality both in United States and Africa. We describe key stakeholder perspectives and priorities related to bringing early-
Externí odkaz:
https://doaj.org/article/c70bdb1e2e38445683572079d0ce2509
Autor:
Li-Chung Tsao, Erika J. Crosby, Timothy N. Trotter, Junping Wei, Tao Wang, Xiao Yang, Amanda N. Summers, Gangjun Lei, Christopher A. Rabiola, Lewis A. Chodosh, William J. Muller, Herbert Kim Lyerly, Zachary C. Hartman
Publikováno v:
JCI Insight, Vol 7, Iss 6 (2022)
Two HER2-specific mAbs, trastuzumab and pertuzumab (T+P), combined with chemotherapy comprise standard-of-care treatment for advanced HER2+ breast cancers (BC). While this antibody combination is highly effective, its synergistic mechanism-of-action
Externí odkaz:
https://doaj.org/article/c87d5137315e42528a934056270a6891
Autor:
Tao Wang, Michael A Morse, Takuya Osada, Herbert Kim Lyerly, Junping Wei, Xiao-Yi Yang, Gangjun Lei, Zachary Conrad Hartman, Pankaj Agarwal, Li-Chung Tsao, Chaitanya R Acharya, Bin-Jin Hwang, Timothy Trotter
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 3 (2022)
Background The majority of colorectal carcinomas (CRCs) are insensitive to programmed death protein-1/programmed death-ligand 1 (anti-PD-1/PD-L1) immune checkpoint inhibitor (ICI) antibodies. While there are many causes for ICI insensitivity, recent
Externí odkaz:
https://doaj.org/article/7313de08ca68445aa4436a03e31eed63
Autor:
Xiao Yang, Tao Wang, Michael A Morse, Takuya Osada, William Gwin, Herbert Kim Lyerly, Cong-Xiao Liu, Pankaj Agarwal, Hiroshi Nagata, Erika J Crosby, Pei Zhong, Shinya Abe, Yoshiyuki Inoue, Kensuke Kaneko, Chaitanya R Acharya, Joshua Snyder
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Externí odkaz:
https://doaj.org/article/f1a40627b3444ff2afb9da9c50ee6a96